Liu told GEN at the time that of the roughly 75,000 cataloged pathogenic mutations in human genetic diseases, prime editing had the versatility and potential to correct the majority (89%) of them. Liu co-founded Prime Medicine to commercialize prime editing based on Anzalone's groundbreaking work when he was a postdoctoral fellow. Anzalone discussed the technology and the company on GEN's "Close to the Edge" video interview series. (Anzalone is Prime's lead developer of prime editing, and the company's scientific co-founder.) Liu and Prime Medicine (which went public last year ) have said they anticipate prime editing joining base editing in human clinical trials in less than a year.